drugset / Trial / NCT00886106

The Effect of High-dose Remifentanil on Established Capsaicin-induced Hyperalgesia in Human Volunteers

NCT00886106

Phase 4 Unknown 24 enrolled Medical University of Vienna
RandomizedCrossoverDouble-blindBasic science

Summary

Treatment of chronic pain is a major clinical challenge since chronic pain is frequent and leads to deterioration of quality of life. An injury or wound can lead to long term changes in the nervous system that make the skin more sensitive at and near the injury; this is termed hyperalgesia and occurs through long term depotentiation (LTP), i.e., a change in the synaptic interaction between neurons. Opioids are the gold standard for the symptomatic therapy of moderate to severe pain. Now, in animal studies the investigators have discovered previously unrecognized effects of opioids. Intradermal injection of capsaicin (injection of pepper extract into the skin) is an established pain model in humans. The investigators want to test the influence of remifentanil, an ultra-short acting opioid, on hyperalgesia observed after intradermal capsaicin in human volunteers in a double blind cross-over prospective active placebo controlled clinical trial.

Timeline

Start
2009-06
Primary completion
2009-12
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Midazolam Small molecule 15 ug/kg Intravenous
Subject Remifentanil Small molecule 0.7 ug/kg Intravenous

Indications

No indication recorded.